Ling W, Shoptaw S, Goodman-Meza D. Subst Abuse Rehabil. 2019;10:69–78.
The authors of this paper have advised that is incorrect. The authors advised that they had listed values for Cmax and Ctrough after a single dose of Brixadi (CAM2038) and not steady state, as it was provided for Sublocade. The new reflects the Brixadi steady state concentrations for a more direct comparison with Sublocade.
The correct is as follows:
Table 1 Comparison of Long-Acting Formulations of Buprenorphine FDA-Approved for Treatment of Opioid Use Disorder